Dadun/></a>
				</td>
				<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Ciencias Cardiovasculares > Trombosis y hemostasia > DA - CIMA - Cardiovasculares - Trombosis y Hemostasia - Artículos de Revista >

The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients
Authors: Montes, R. (Ramón)
Nantes, O. (Oscar)
Alonso, A. (Alvaro)
Zozaya, J.M. (José Manuel)
Hermida, J. (José)
Keywords: Anticoagulants
Genetics
Haemorrhage
Issue Date: 2008
Publisher: Blackwell Publishing
Publisher version: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2008.07414.x/abstract
ISSN: 1365-2141
Citation: Montes R, Nantes O, Alonso A, Zozaya JM, Hermida J. The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients. Br J Haematol 2008 Dec;143(5):727-733.
Abstract
The VKORC1 c.-1639G>A and CYP2C9 c.430C>T and c.1075A>C polymorphisms have been associated with increased sensitivity to oral anticoagulants. However, their role in gastrointestinal bleeding is unknown. We studied the risk of gastrointestinal bleeding associated with these polymorphisms, and how this risk was influenced by the anticoagulant dose and the use of common drugs. Eighty-nine patients with gastrointestinal bleeding during acenocoumarol therapy and 177 patients free of bleeding during acenocoumarol therapy were studied. None of the three polymorphisms constituted a serious gastrointestinal bleeding risk factor. However, patients bearing at least one of these polymorphisms were at high risk, when they simultaneously met one of the following conditions: a weekly dose of acenocoumarol higher than 15 mg [adjusted Odds Ratio (OR) (95% confidence interval (CI) = 4.19 (1.59-11.04)]; amiodarone use [adjusted OR (95% CI) = 9.97 (1.75-56.89)]; or aspirin use [adjusted OR (95% CI) = 8.97 (1.66-48.34)]. The consumption of statins was associated with a lower risk of gastrointestinal bleeding [adjusted OR = 0.50 (0.26-0.99)]. The risk of gastrointestinal bleeding during acenocoumarol therapy in carriers of any of the studied polymorphisms is severely increased with exposure to weekly doses of acenocoumarol higher than 15 mg or the use of amiodarone or aspirin.
Permanent link: http://hdl.handle.net/10171/21984
Appears in Collections:DA - CIMA - Cardiovasculares - Trombosis y Hemostasia - Artículos de Revista

Files in This Item:

There are no files associated with this item.

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.